Major histocompatibility complex class I antigen presentation (MHC-I antigen presentation)

The term "Cytotoxic T lymphocyte activation via MHC class I presentation" refers to a **biological process**, not a single molecule or receptor. This process involves the display of intracellular peptides on the cell surface by major histocompatibility complex class I (MHC-I) molecules. All nucleated cells express MHC-I proteins, which bind peptides generated from proteasomal degradation of cytosolic proteins. These peptide-MHC complexes are transported to the cell surface where they can be recognized by cytotoxic CD8+ T lymphocytes (CTLs). Recognition of non-self or abnormal peptides—such as those derived from viruses or tumor-specific mutations—triggers CTL-mediated killing of the presenting cell[2][4][6]. Defects in this pathway are common mechanisms for immune evasion in cancers and viral infections[1][5]. The molecular machinery involved includes proteasomes/immunoproteasomes, TAP transporters, tapasin chaperones, and other components that ensure proper peptide loading onto MHC-I molecules before their display at the plasma membrane[5][6]. **Note:** This is not a canonical drug target such as an enzyme or receptor but rather describes an essential immunological mechanism/process. If you require information about specific molecular targets within this pathway (e.g., "MHC class I molecule," "TAP transporter," etc.), please specify further[2][4].

Other names

MHC class I pathwayMHC-I antigen processing and presenting machineryendogenous antigen presentation pathwaycytosolic pathway